Stock Track | BioMarin Pharmaceutical Soars 5.30% Intraday on Positive Analyst Ratings and Upcoming Investor Conferences

Stock Track

Feb 24

BioMarin Pharmaceutical's stock surged 5.30% during intraday trading on Tuesday, following a series of positive analyst updates and the company's announcement of increased investor engagement.

The price movement comes after Evercore ISI and Cantor Fitzgerald both reaffirmed their Buy ratings on the stock, with price targets of $110 and $85 respectively. Additionally, Oppenheimer maintained coverage with a revised price target of $95, down from $98, while still indicating a positive outlook.

Investor sentiment was further bolstered by BioMarin's announcement that its management will participate in four investor conferences in March 2026, including events hosted by TD Cowen, Leerink, Jefferies, and Barclays. These appearances are expected to enhance the company's visibility and communication with the investment community.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1104772958"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1104772958\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1104772958?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 22:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104772958","market":"hk","top_or_hot":-1,"title":"Stock Track | BioMarin Pharmaceutical Soars 5.30% Intraday on Positive Analyst Ratings and Upcoming Investor Conferences","media":"Stock Track","content":"<p>BioMarin Pharmaceutical's stock surged 5.30% during intraday trading on Tuesday, following a series of positive analyst updates and the company's announcement of increased investor engagement.</p><p>The price movement comes after Evercore ISI and Cantor Fitzgerald both reaffirmed their Buy ratings on the stock, with price targets of $110 and $85 respectively. Additionally, Oppenheimer maintained coverage with a revised price target of $95, down from $98, while still indicating a positive outlook.</p><p>Investor sentiment was further bolstered by BioMarin's announcement that its management will participate in four investor conferences in March 2026, including events hosted by TD Cowen, Leerink, Jefferies, and Barclays. These appearances are expected to enhance the company's visibility and communication with the investment community.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BioMarin Pharmaceutical Soars 5.30% Intraday on Positive Analyst Ratings and Upcoming Investor Conferences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BioMarin Pharmaceutical Soars 5.30% Intraday on Positive Analyst Ratings and Upcoming Investor Conferences\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-24 22:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BioMarin Pharmaceutical's stock surged 5.30% during intraday trading on Tuesday, following a series of positive analyst updates and the company's announcement of increased investor engagement.</p><p>The price movement comes after Evercore ISI and Cantor Fitzgerald both reaffirmed their Buy ratings on the stock, with price targets of $110 and $85 respectively. Additionally, Oppenheimer maintained coverage with a revised price target of $95, down from $98, while still indicating a positive outlook.</p><p>Investor sentiment was further bolstered by BioMarin's announcement that its management will participate in four investor conferences in March 2026, including events hosted by TD Cowen, Leerink, Jefferies, and Barclays. These appearances are expected to enhance the company's visibility and communication with the investment community.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BMRN","symbol_name":"拜玛林制药","start_time":0,"source_url":"","article_id":"1104772958","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104772958","pubTimestamp":1771944414,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"BioMarin Pharmaceutical's stock surged 5.30% during intraday trading on Tuesday, following a series of positive analyst updates and the company's announcement of increased investor engagement.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BMRN":"拜玛林制药"},"translate_title":"个股追踪|拜玛林制药盘中大涨5.30%，因分析师正面评级和即将召开的投资者会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMRN":1},"content_text":"BioMarin Pharmaceutical's stock surged 5.30% during intraday trading on Tuesday, following a series of positive analyst updates and the company's announcement of increased investor engagement.The price movement comes after Evercore ISI and Cantor Fitzgerald both reaffirmed their Buy ratings on the stock, with price targets of $110 and $85 respectively. Additionally, Oppenheimer maintained coverage with a revised price target of $95, down from $98, while still indicating a positive outlook.Investor sentiment was further bolstered by BioMarin's announcement that its management will participate in four investor conferences in March 2026, including events hosted by TD Cowen, Leerink, Jefferies, and Barclays. These appearances are expected to enhance the company's visibility and communication with the investment community.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}